Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Dana-Farber Cancer Institute Stories

2011-03-28 04:00:00

Innovative international research consortium's first study opens SAN FRANCISCO, March 28, 2011 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI, voiced as "Alchemy") today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States. CASTLE stands for Collaborative Advanced Stage Tissue Lung Cancer study. (Photo:...

2011-03-25 19:04:34

First drug approved in more than a decade The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade. "Ipilimumab is the first in a new class of drugs that has been shown to offer a survival benefit for metastatic melanoma, which is often a fatal disease, and hopefully, this will lead to the development of related treatments for...

2011-03-24 08:30:00

BOSTON, March 24, 2011 /PRNewswire/ -- John Legere, CEO of Global Crossing, is nearing the finish line of his goal to raise $1 million for cancer research at Dana-Farber Cancer Institute. On April 18, Legere will run in the 115th Boston Marathon, his seventh as a member of the Dana-Farber Marathon Challenge team. He is the all-time leading fundraiser for the Dana-Farber Marathon Challenge and is less than $150,000 away from reaching his $1 million goal. "This is a remarkable...

07c605cfe9cf2854ff18c15b2aa8389a1
2011-03-24 05:40:00

Scientists reported on Wednesday that they have sequenced the entire genetic code of 38 multiple myeloma patients, and have uncovered the most likely genetic causes of the aggressive blood cancer. The work, carried out by 21 institutions in the U.S. and Canada, offers the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, and provides new and unexpected insights into the events that lead to the disease. "For the first time, we are able to see on a molecular...

2011-03-15 20:39:13

Promising strategy moves quickly to human trials Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis. The pre-clinical results, which will appear in the April issue of the journal Genes & Development and is currently published on its web site, have already prompted the opening of a small clinical trial in patients with advanced...

677d01043d4db3738e5ed823fb66fe49
2011-02-10 08:38:50

Using whole genome sequencing and multiple tumor samples, researchers uncover genes tied to prostate cancer growth For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical...

2011-02-02 20:27:46

Finding lays the groundwork for gene-based test Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to...

2010-12-23 18:03:23

Suggests potential strategy for repairing injured hearts By tweaking a single gene, scientists have mimicked in sedentary mice the heart-strengthening effects of two weeks of endurance training, according to a report from Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC). The genetic manipulation spurred the animals' heart muscle cells -- called cardiomyocytes -- to proliferate and grow larger by an amount comparable to normal mice that swam for up to three hours a...

2010-12-09 09:32:00

In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec. 9, 2010 /PRNewswire-USNewswire/ -- A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose...

b87993d1b33f05fb0360ed2a92fae0481
2010-12-09 10:45:43

In early results, all participants responded to treatment with limited side effects A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib...